Horacio Vall
VP Science and Technology @ LabCorp
Los Angeles, United States
Horacio Vall is a startup investor at LabCorp in Los Angeles. Horacio Vall - VP Science and Technology @ LabCorp
Last updated:
For AI agents: llms.txt
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
About LabCorp
Labcorp specializes in providing physicians with laboratory tests. They develop new tests that provide enhanced accuracy and additional clinical information. Their customers include physicians and their patients, hospitals and managed care plans, private employers, military and law enforcement agencies, and pharmaceutical and biotechnologycompanies.
LabCorp Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Steven Anderson
Global Head of Clinical Trials
|
|||
|
Amy B. Summy
Executive Vice President & CMO
|
|||
|
Araceli Reyes
Divisional Medical Director, Northeast Division
|
|||
|
Arthur Zebelman
Technical Director
|
|||
|
Horacio Vall
VP Science and Technology
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
How do I contact Horacio Vall?
Public channels for Horacio Vall include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!